Loading…
← CockpitCompetitor Analysis › 688513.SS Chengdu Easton Biopharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A688513.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chengdu-based biopharmaceutical manufacturer selling drugs in China.

Momentum weak 24
Mkt cap
$1.03B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$13.4M
20-day average traded
Fwd P/E
24.6×
forward earnings
ROIC−WACC
+6.4 pp
WACC 5.0%
Hurdle
-3 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥38.82
1D-3.2%
1W-13.5%
1M-18.9%
3M-22.9%
6M-33.1%
YTD-36.9%
1Y-30.8%
ATR %6.3%
52w lowhigh51.8% off high

What Chengdu Easton Biopharmaceuticals does

Chengdu-based biopharmaceutical manufacturer selling drugs in China.

Where it sits in the supply chain

  • Pharmaceuticals
  • Biopharma

Moat: none

Headquarters: Chengdu, China · Employees: 1,480

Chengdu Easton Biopharmaceuticals at a glance

Size Chengdu Easton Biopharmaceuticals (688513.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 2110th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.82 on 18 Nov 2026.

Performance Over six months the shares fell 33.1%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 2.0% over the last twelve months (peer median +7.7%); the operating margin is 12.9% (peer median 8.7%).

Valuation It trades at 24.6× forward earnings against a peer median of 18.3× (4th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 92688513.SS 70
Six months, rebased to 100: Chengdu Easton Biopharmaceuticals against the median of its 20 peers (local-currency closes).

Chengdu Easton Biopharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.30BCN¥1.32BCN¥1.34BCN¥1.11BCN¥1.16B
Revenue growth—-1%+21%-4%—
Gross profitCN¥1.03BCN¥940MCN¥956MCN¥840MCN¥933M
EBITDAn/aCN¥276MCN¥253MCN¥229MCN¥217M
Net incomeCN¥273MCN¥284MCN¥238MCN¥227MCN¥247M
Free cash flowCN¥170MCN¥179MCN¥146MCN¥100.0M-CN¥187M
Capital expenditureCN¥90.5MCN¥86.3MCN¥117MCN¥175MCN¥339M
Total debtCN¥263MCN¥191MCN¥156MCN¥270MCN¥117M

Quarterly statements and history in the cockpit →

Chengdu Easton Biopharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%3004974553002737300702000650SVRA4887BSLN600789BLUEJET1952688091605116688710AARTIPHARM688382SPTXPGHL688513.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Chengdu Easton Biopharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×20×40×60×30049745530027373007020006504887BSLNBLUEJET1952688710600129PGHL688513.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chengdu Easton Biopharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%3004974553002737000650BSLNBLUEJET605116688710600557688382688513.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chengdu Easton Biopharmaceuticals is the large dot.

Chengdu Easton Biopharmaceuticals competitors and peer comparison

How Chengdu Easton Biopharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chengdu Easton Biopharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure688513.SSPeer medianRank in peer set
1-month return-18.9%-5.0%3rd lowest of 21
6-month return-33.1%-10.6%3rd lowest of 21
Distance from 52-week high-51.8%-32.1%3rd lowest of 21
Revenue growth (TTM)-2.0%+7.7%6th lowest of 19
Operating margin12.9%8.7%9th highest of 19
Forward P/E24.6×18.3×4th most expensive of 15
Growth the price implies (Req g, 7 yrs)4.4%2.5%6th most demanding of 14
Growth delivered (Del g)+7.7%+6.5%7th highest of 14
Hurdle (Req g minus delivered)-3.3 pp-3.6 pp7th most demanding of 14
ROIC minus cost of capital+6.4 pp+0.1 pp4th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%

Questions

Which companies are Chengdu Easton Biopharmaceuticals's closest peers?
The cockpit's peer set: Jiangxi Fushine Pharmaceutical (300497.SZ), Towa Pharmaceutical (4553.T), Sunflower Pharmaceutical (002737.SZ), Zhejiang Tianyu Pharmaceutical (300702.SZ), Renhe Pharmacy (000650.SZ), Savara (SVRA), SAWAI (4887.T), Basilea Pharmaceutica (BSLN.SW).
Is Chengdu Easton Biopharmaceuticals expensive compared with its peers?
On forward p/e it trades at 24.6× against a peer median of 18.3×, 4th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Chengdu Easton Biopharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -33.1% against -10.6% for the median peer; over one year -30.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.